A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix - BEATcc

Takekuma Munetaka0 个研究点目标入组 56 人开始时间: 2019年6月5日最近更新: 2024年5月27日

适应症

试验速览

阶段: 3 期
状态: 进行中（未招募）
发起方
入组人数: 56

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: Female

入选标准

•1. Female patients must be 18 and more years of age.
•2. Signed informed consent before any study-specific procedure
•3. Able (in the investigator's judgment) to comply with the study protocol
•4. GOG/Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
•5. Life expectancy 3 and more months
•6. Histologically- or cytologically-confirmed diagnosis of metastatic (stage IVB), persistent, or recurrent cervical cancer (histologies other than squamous cell, adenocarcinoma, or adenosquamous will be excluded) not amenable for curative treatment with surgery and/or radiation therapy. The inclusion of patients with adenocarcinoma histology will be capped to 20% of the whole study population.
•7. No prior systemic anti-cancer therapy for metastatic or recurrent disease.
•- Concurrent chemo-radiotherapy treatment with curative intent or adjuvant chemo-radiotherapy must have been completed 3 and more months (90 days) prior to enrollment
•- Palliative radiation therapy (e.g., for pain or bleeding) 6 weeks prior enrollment is allowed as long as this does not affect measurable disease and patients are recovered from its symptoms.
•8. Measureable disease by RECIST v1.1 criteria: Patients must have at least 1 target lesion to be used to assess response on this protocol as defined by RECIST v1.1. If the only target lesion is limited to the radiation field, a biopsy is required to confirm malignancy.
•9. A tumor specimen is mandatory at study entry. This may be an archival biopsy or, in its absence, a tumor biopsy obtained within 3 months of randomization from a non-irradiated lesion. Paired recent biopsies at baseline (lesion not previously irradiated; within 3 months of randomization) and at progression disease will not be mandatory, nevertheless they are encouraged as long as these are feasible.
•10. Adequate organ function:
•- Hemoglobin 9 and more g/dL (transfusion permitted)
•- ANC 1.5x10^9/L and more
•- Lymphocyte count 0.5x10^9/L and more
•- Platelet count 100x10^9/L and more
•11. Adequate liver function:
•- Serum albumin 2.5 g/dL and more
•- Total serum bilirubin 1.5xULN and less
•- AST and ALT 2.5xULN and less or 5xULN and more if tumor involvement (liver) is present
•12. Adequate renal function:
•- Patients with serum creatinine less than 1.5xULN
•- Urine dipstick for proteinuria less than 2+. Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate 1 and more g of protein in 24 hours or urine protein/creatinine (UPC) ratio of 1.0
•13. Adequate coagulation:
•- Blood coagulation parameters (PTT, PT/INR): PT such that international normalized ratio (INR) is 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and PTT less than 1.5xULN
•14. Negative Test Results for Hepatitis
•15. Toxicities related to previous treatments must be recovered to less than grade 2 (with the exception of alopecia).
•16. Female participants must be postmenopausal (12 and more months of non-therapyinduced amenorrhoea) or surgically sterile (absence of ovaries and/or uterus, or who received therapeutic radiation to the pelvis) or otherwise have a negative serum pregnancy test within 7 days of the first study treatment and agree to abstain from heterosexual intercourse or use single or combined contraceptive methods that result in a failure rate of less than 1% per year during th

排除标准

•1.Disease that is suitable for local therapy administered with curative intent
•2.Prior radiotherapy delivered using cobalt (rather than a linear accelerator)
•3.Patients with Stage IVA not amenable to concurrent chemo-radiation as primary treatment will not be eligible.
•4.Ongoing disease involving the bladder or rectum at screening/baseline:
•- In patients with pelvic disease, absence of tumor in the bladder or rectal mucosa must be demonstrated by MRI (preferred method, or endoscopy/cystoscopy if MRI is not easily accessible) within 28 days before enrolment
•5.Evidence of abdominal free air
•6.Bilateral hydronephrosis, unless it can be alleviated by ureteral stent(s) or percutaneous drainage
•7.Patients previously treated with chemotherapy except when used concurrently with radiation therapy. Patients who have received either concurrent paclitaxel with radiation therapy or carboplatin/paclitaxel as neoadjuvant or adjuvant therapy are ineligible for the study.
•8.Prior treatment with any anti-VEGF drug, including bevacizumab, CD137 agonists or immune checkpoint blockade therapies, anti-PD1, or anti-PDL1 therapeutic antibodies or anti-CTLA 4.
•9.Patients with a concomitant malignancy other than non-melanoma skin cancer. Patients with a prior invasive malignancy (except non-melanoma skin cancer) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy.
•10.Known brain metastases or spinal cord compression. It is mandatory to perform a scan of the brain in cases of suspected brain metastases (CT or MRI) or spinal cord compression (MRI).
•11.History or evidence, following a neurological examination, of central nervous system disorders, unless properly treated with standard medical treatment. History of cerebrovascular accident, transient ischemic attack or subarachnoid hemorrhage within six months of the first date of treatment on this study.
•12.Patients with serious non-healing wound, ulcer, or bone fracture. This includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess for which an interval of 6 months must pass before study entry. In addition, the patient must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
•13.Acute intestinal obstruction or sub-occlusion episode in the last 6 months
•14.Active GI bleeding or GI ulcer
•15.History of Crohn's disease or inflammatory bowel disease
•16.Prior bowel resection 6 and more weeks preceding the first study dose
•17.History of diverticulitis requiring medical intervention
•18.NCI CTCAE (ver 5.0) G2 or less enteritis
•19.Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1, Cycle 1 (C1D1).
•20.Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to C1D1.
•21.Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
•22.Current or recent (within 10 days before the first dose of study drug) chronic daily treatment with aspirin (above 325 mg/day), clopidogrel (above 75 mg/day), or current or recent (within 10 days before first dose of bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes.
•23.Patients with pre-existing G2 or greater

研究者

发起方

Takekuma Munetaka

相似试验

进行中（未招募）

1 期

Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the CervixMetastatic (stage IVB), Persistent, or Recurrent Carcinoma of the CervixMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-000367-83-SEGrupo Español de Investigación en Cáncer de Ovario (GEICO)404

进行中（未招募）

1 期

EUCTR2018-000367-83-NOGrupo Español de Investigación en Cáncer de Ovario (GEICO)404

招募中

3 期

Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervix

2024-514179-17-00Grupo Espanol De Investigacion En Cancer De Ovario339

进行中（未招募）

1 期

Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervix

EUCTR2018-000367-83-DEGrupo Español de Investigación en Cáncer de Ovario (GEICO)404

进行中（未招募）

1 期

Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervix

EUCTR2018-000367-83-ESGrupo Español de Investigación en Cáncer de Ovario (GEICO)404